We provide biomarker- and companion diagnostics (CDx) services to the biopharmaceutical industry for precision medicine in cancer immunotherapy.
We seek academic and industrial collaborators as well as seed financing from investors on our way to become a leading provider of CDx in the growing field of cancer immunotherapy.
Cancers evade the immune system by activating the AHR, which leads to tumor promotion and the suppression of anti-tumor immunity. Our technology enables high-resolution assessment of AHR activity of cancers, supporting clinical development and drug selection for optimized therapy.
The core of our business
is to provide biomarker services to the biopharmaceutical industry during preclinical and clinical development of new cancer immunotherapies. Mid- to long-term, we plan to bring new, innovative CDx to cancer patients throughout the world.